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A Prevalent Mutation with Founder Effect in
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Nadem Soufir1,11, Cecile Ged2,3,4,11, Agnes Bourillon1, Frederic Austerlitz5, Ce´cile Chemin2,3,4, Anne Stary6,
Jacques Armier6, Daniele Pham6, Khadija Khadir7, Joelle Roume8, Smail Hadj-Rabia9, Bakar Bouadjar10,
Alain Taieb2,3,4, Hubert de Verneuil2,3,4, Hakima Benchiki7,11, Bernard Grandchamp1,11 and Alain Sarasin5,11
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder that is associated with an inherited defect of the
nucleotide excision repair pathway (NER). In this study, we investigated the involvement of XP genes in
86 XP patients belonging to 66 unrelated families, most of them consanguineous and originating from Maghreb.
Sequencing analysis was performed either directly (44 probands) or after having previously characterized the involved
XP gene by complementation assay (22 families). XPC and XPA mutations were respectively present in 56/66 and 8/66
probands. Strikingly, we identified the same homozygous frameshift mutation c.1643_1644delTG (p.Val548AlafsX25) in
87% of XP-C patients. Haplotype analysis showed a common founder effect for this mutation in the Mediterranean
region, with an estimated age of 50 generations or 1,250 years. Among 7/8 XP-A patients, we found the previously
reported nonsense homozygous XPAmutation (p.Arg228X). Six mutations—to our knowledge previously unreported—
(five in XPC, one in XPA) were also identified. In conclusion, XPC appears to be the major disease-causing gene
concerning xeroderma pigmentosum in North Africa. As the (p.Val548AlafsX25) XPC mutation is responsible for a huge
proportion of XP cases, our data imply an obvious simplification of XP molecular diagnosis, at least in North Africa.
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INTRODUCTION
Xeroderma pigmentosum (XP) is a rare, autosomal, recessive
syndrome, described as early as 1870, as a sun-hypersensi-
tivity disorder associated with numerous skin abnormalities
such as excessive freckling, hyper- and hypopigmentation,
poikilodermia, skin atrophy, skin aging, and a very high rate
of early and multiple skin cancers (Cleaver, 1968; Takebe
et al., 1989; Bootsma et al., 1995). Ocular abnormalities
including photophobia, keratitis, ectropion, and tumors are
also frequent. About 20–30% of XP patients show major
neurological disorders characterized by premature neuronal
death, progressive mental retardation and microcephaly
(Kraemer et al., 1987). Genetic defects in XP involve the
repair pathway of bulky DNA damage, such as UV-induced
DNA lesions, that are mainly repaired by the nucleotide
excision repair pathway (NER) (Stary and Sarasin, 2002).
Seven NER XP complementation groups, XP-A to XP-G,
have been characterized. Two NER sub-pathways have
been described. A fast repair of DNA lesions located on
actively transcribed genes, called transcription-coupled repair
(TCR) and a slower repair of lesions located on the rest
of the genome, called global genome repair (Sarasin and
Stary, 2007).
In addition, an XP variant group has also been described
that involves a DNA translesional synthesis polymerase, Pol
eta (Masutani et al., 1999, 2008). These patients have a
normal NER level but their cells are hypermutable following
UV irradiation.
The most prevalent NER defective groups comprising
approximately 90% of characterized classical XP patients, are
XP-C (Europe and North Africa), XP-A (especially in Japan
and North Africa) and XP-D (in Europe and USA). The
remaining 10% are composed of groups B, E, F, and G, with
less than 40 patients recorded in each category (Stary and
Sarasin, 2002).
Several XP mutations have been described through
different countries with a relatively small number of patients
for each analysis (Li et al., 1993; Nishigori et al., 1993;
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Chavanne et al., 2000; Khan et al., 2006; Cleaver et al.,
2007). A recent analysis estimated the incidence of XP for the
autochthonic western European populations to be close to
0.9 affected cases per million live births (Kleijer et al., 2008).
Yet, incidence is much higher in North Africa and because
some of these patients have been treated in France, we aimed
at characterizing the spectrum of XP mutations in a large
cohort of patients originating mainly from Morocco, Algeria,
Tunisia.
RESULTS
We describe a cohort of 86 patients from 66 unrelated XP
families with XP features studied either by direct gene
sequencing or following DNA repair analysis and comple-
mentation assays. The direct gene-sequencing assay included
44 probands, whereas the DNA repair assay analyzed 22
probands from unrelated XP families. We sequenced the XPC
and XPA genes at first, then ERCC2/XPD, XPV/POLH, XPB,
XPE, XPF and XPG genes, if no mutation had been detected.
All mutations identified in the probands were also present in
affected relatives.
In this study, the largest ever reported XP cohort, XPC and
XPA defects were the most frequent, 56/66 (85%) and 8/66
(12%), respectively (Table 1). In two patients (3%), no
mutations were identified in any XP gene.
XPA mutations
The same XPA mutation, the nonsense mutation c.682C4T
p.Arg228X was observed in 7 of 8 XP-A patients. All patients
were homozygous for this mutation and consanguinity was
Table 1. Molecular analysis of XP patients
Geographic Proband Mutant Molecular defects
Patient identification origin number Gene alleles Location DNA level Protein level
Direct sequencing analysis 44
B4-B67-B134-B860 -Bx29-Bx50 Northern Africa 6 XPA 12 Exon 6 c.682C4T homoz p.Arg228X
O5-O10-O16-O26-O46-O62-O76-O80-
O96-O104-O110-O114-O119-O120-
O126-O144 -O151-O175-O184-O203-
O242-O250-B946-B947-B948-B971-
B973-B950-Bx23-Bx36-Bx40-Bx46-
Bx52-Bx55
Northern Africa 33 XPC 66 Exon 9 c.1643_1644delTG
homoz
p.Val548AlafsX25
Spain 1 2
Bx41 Northern Africa 1 XPC 2 Exon 6 c.652delT homoz p.Phe218SerfsX41
Bx28 Chile/West
Indies
1 XPC 1 Exon 9 c.1243C4T p.Arg415X
1 Exon 13 c.2287delC p.Leu763CysfsX4
DNA repair assay 22
AS689 Northern Africa 1 XPA 2 IVS4 c.609_2A4G homoz —
AS858 Northern Africa 1 XPA 2 Exon 6 c.682C4T homoz p.Arg228X
AS185-AS188-AS202-AS233-AS373-
AS629-AS664-AS673-AS694-AS731-
AS769-AS798-AS802-AS820-AS821
Northern Africa 14 XPC 30 Exon 9 c.1643_1644delTG
homoz
p.Val548AlafsX25
Spain 1
AS860 Northern Africa 1 XPC 2 Exon 6 c.658C4T homoz p.Arg220X
AS268 Greece 1 XPC 2 IVS6 c.779+1_14del12
homoz
—
AS704 France 1 XPC 1 Exon 9 c.1243C4T p.Arg415X
1 c.1399C4T p.Gln467X
AS314 France 1 XPC 1 Exon 9 c.1243C4T p.Arg415X
1 c.1704T4A p.Tyr568X
AS751 France 1 XPC 2 Exon 11 c.2092_2093insGTG
homoz
p.Val696Val697InsVal
The analysis was performed by sequencing of the coding regions following amplification from genomic DNA.
In bold characters: the six mutations identified in this work that are, to our knowledge, previously unreported. In italic characters: the recurrent XPC
mutation in exon 9.
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documented in all corresponding Maghrebi families. In
addition, we also characterized a splicing XPA homozygous
mutation, c.609_2A4G, which to our knowledge has not
been described (Table 1). All but one of XP-A patients
displayed neurological symptoms (mental retardation and/or
spasticity and/or hyporeflexia and/or ataxia). Interestingly,
although XP-A and C patients had both pronounced photo-
sensitivity, XP-A patients had fewer skin cancers (30%) than
XP-C patients (75%, P-value o0.05 after adjusting on age).
XPC mutations
A single mutation located in the ninth exon of the XPC gene
(c.1643_1644delTG, p.Val548AlafsX25) was present at a
very high frequency in our XP patients. Mutation frequency
was 74% (49 of 66) in all the XP probands tested and 87% (49
of 56) in XP type C patients, mostly from the Maghreb
countries. The prevalence of this mutant was 96% (50 of 52)
in Maghrebi XP-C patients. Noticeably, because of high
consanguinity levels in the Maghreb country, the mutation
was present at the homozygous state in all the patients
studied. The great majority of the patients with the founder
mutation had the same clinical features, i.e., pronounced
photosensitivity, numerous skin cancers, and ophthalmolo-
gical signs. Yet, two of them had neurological symptoms.
One patient from a consanguineous family had mental
retardation, microcephaly, deafness, spasticity, and ataxia.
The only available information for the second patient was the
presence of a mental retardation. Six patients, all being less
than 5 years old did not have any skin cancer.
Three other previously described mutations were observed
in four patients (Table 1 and see Supplementary Table S2
online). The nonsense mutation located in exon 9 (c.1243C4T,
p.Arg415X) previously reported in one patient (Khan et al.,
2006) was found in two patients at the heterozygous state.
The homozygous c.658C4T (p.Arg220X) mutation has been
already described in a patient (Chavanne et al., 2000). The
valine insertion in exon 11 c.2092_2093insGTG (p.Val696_
Val697insVal) reported in two patients (Li et al., 1993;
Cleaver et al., 2007) was present in one patient from France
at the homozygous state.
Five mutations to our knowledge previously unreported
are observed in this report including two frameshifts in exons
6 and 13, a splice mutation in intron 6, and 2 nonsense
mutations in exon 9 (Table 1 and Supplementary Table S2).
The frameshift in exon 6 (c.652del T, p.Phe218SerfsX41) is
present at the homozygous state in a consanguineous family
from North Africa. The frameshift in exon 13 (c.2287delC,
p.Leu763CysfsX4) is observed at the heterozygous state. The
second mutant allele is a nonsense in exon 9 (c.1243C4T,
p.Arg415X) in a family originating from Chile (mother) and
the French West Indies (father’s mother). The splicing
mutation c.779þ 1_14del12, present at the homozygous
state in a patient from Greece, abolishes the splicing donor
site of exon 6, as shown by the bioinformatics programs
‘‘BDGP (www.fruitfly.org/seq_tools/splice.html)’’. Moreover,
this mutation does not appear in public SNP databases.
The nonsense mutations (c.1399C4T, p.Gln467X, and
c.1704T4A, p.Tyr568X) located in exon 9 are present in two
compound heterozygous unrelated French patients who also
carried c.1243C4T (p.Arg415X) as the second mutant allele.
Finally, two patients from the direct sequencing study had
no mutation in XPC, XPA, XPD/ERCC2, and XPV/POLH
genes. Therefore, the remaining XP genes (XPB, XPE, XPF,
XPG) were entirely sequenced in these two patients, but no
mutation was detected.
Haplotype analyses were performed in all patients
carrying the XPC c.1643_1644delTG, p.Val548AlafsX25
mutation, and in 49 unrelated healthy controls from North
Africa. The common mutation c.1643_1644delTG was
systematically associated with a unique rare haplotype
including the same allele of the two intragenic XPC
microsatellites, along with c.1-27 G, IVS5 þ 44 C, IVS8-22
A, c.1475 G (p.492R), c.1496 C (p.499A), c.2061 G (p.687R),
IVS12-37 C, IVS12-6 A, IVS15þ 28 C, IVS14-40 A, c.2815 C
(p.939Q).
Further haplotype analysis of 11 microsatellites surround-
ing XPC (Supplementary Table S1) revealed a frequent
common haplotype comprising specific alleles of 22GT3/
26TG/D3S1554/RH5658/D3S3613 encompassing the XPC
locus, present in 1/3 of patients. By using the method
developed by Austerlitz et al. (2003), we estimated an age
of 50 generations or 1,250 years (confidence interval¼
(1,090–1,495)), assuming a 25-year generation time, for the
common XPC mutation c.1643_1644delTG. This estimate
was of 1,000 years (confidence interval¼ (870–1,200)) assuming
a 20-year generation time or 1,500 years (confidence
interval¼ (1,310–1,790)) for a 30-year generation time
(Tremblay and Vezina, 2000).
DISCUSSION
We report here the largest group of XP patients analyzed so far
for eight DNA repair genes, XPC, XPA, XPD/ERCC2, XPB, XPE,
XPF, XPG, and XPV/POLH. As previously suggested (Cleaver,
1968; Bootsma et al., 1995), we can clearly conclude from this
work that XP types C and A are the most frequent XP groups, at
least in Southern Europe and North Africa.
XPA mutations were present in 12% of XP patients, a
prevalent mutation—R228X—being present in 87.5% of XP-
A patients. The frequency of this mutation had already been
described in North Africa, with similar results to our data
(Nishigori et al., 1993; Cleaver et al., 1999).
XPC mutations were identified in 56 of 66 (85%)
probands. The common XPC mutation, c.1643_1644delTG
(p.Val548AlafsX25), present at the homozygous state in 87%
of XP-C patients, has been previously reported in 24 XP-C
patients; 21 homozygous patients originated from North
Africa mainly Tunisia (Li et al., 1993; Khan et al., 2006;
Mahindra et al., 2008, Ben Rekaya et al., 2009), and three
patients from Italy, Egypt, and Africa, respectively (Chavanne
et al., 2000; Ridley et al., 2005). Two heterozygous patients
(XP132BE and XP30BE) originated from USA and Honduras
(Khan et al., 2006).
As previously shown, this common mutation results in the
absence of XPC protein because it leads to a frameshift
mutation (Rezvani et al., 2008). The DNA repair ability
induced by this mutation has previously been found only to
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be 20% of proficient normal cells (Chavanne et al., 2000). At
least in our experimental conditions, the level of DNA repair
is less than 10% of normal cells and can be totally
complemented to the normal level by transduction of the
wild-type XPC gene via recombinant retroviruses (data not
shown).
Two patients carrying this mutation had neurological
signs, which were for one patient indistinguishable from
those observed in XP-A patients. Neurological impairment
was recently described in a consanguineous XP-C family
harboring a homozygous mutation in the initiation codon of
XPC, whereas neurological symptoms were absent in another
family carrying the same mutation (Khan et al., 2009).
Possible hypotheses accounting for the neurological abnorm-
alities in these patients could be the presence, in case of
consanguinity, of homozygous mutation in another (uniden-
tified) gene, or could result from the interaction of modifier
genes with XPC on neurological phenotype.
As the mutation was predominant in Maghreb and also
characterized in Egyptian, Italian, and Spanish patients, it
highly suggested a common founder effect in the Mediterra-
nean region. By using already described mathematical tools
based on microsatellites haplotyping, we were able to
calculate that the common ancestor mutation occurred
1,250 years ago. Interestingly, this date approximately
corresponds to the beginning of the European invasion by
Muslims from Arabia (the ‘‘Saracens’’).
Four of eight patients who did not originate from North
Africa were compound heterozygotes for XPC mutations
(Table 1 and Supplementary Table S2).
A particular mutation was the nonsense mutation located
in exon 9 (c.1243C4T, p.Arg415X), present in three different
French families (Table 1). It has been previously described at
the heterozygous state in two French siblings (XP314VI and
XP315VI) whose second mutant allele was not identified at
that time (Khan et al., 2006). The French patient AS704 also
carries a nonsense mutation to our knowledge previously
unreported on the second allele (c.1399C4T, p.Gln467X). In
the third French patient (Bx28) the p.Arg415X mutant had a
paternal origin and the father’s mother originates from the
French West Indies. The second mutant allele was a
frameshift in exon 13 (c.2287delC, p.Leu763CysfsX4), and
originated from the mother (Chile).
Five XPC mutants to our knowledge previously unreported
have been identified in this study (Table 1 and Supplemen-
tary Table S1). With the mutations reported in this work,
a total of forty-five inactivating XPC mutations have been
characterized in XP-C patients (Supplementary Table S2).
Most of them are frameshift (deletion and insertion) or
nonsense (substitution), leading to a truncated XPC protein.
A few splicing and missense mutations are also encountered.
However, there is no obvious correlation between genotype
and phenotype or survival.
In our total of 66 XP probands, we did not find any
mutations in the eight-screened XP genes in two families, one
of which was consanguineous. Unfortunately, fibroblast
cultures were not available to confirm the DNA repair defect.
In these families, the genetic defect might be an XP mutation
localized outside the coding sequence and/or a complex
rearrangement of an XP gene.
Xeroderma pigmentosum group C, the most common form
of XP in Europe and North Africa, is characterized by high
morbidity and early mortality, essentially because of the
striking accumulation of skin cancers on the exposed body
sites. Early diagnosis in these patients is particularly
important, because XP-C patients show a normal neurology
and an early full protection against sun-exposure has already
shown to allow them to have almost a normal life. The high
frequency of the same mutation in patients from North Africa
will considerably simplify the molecular diagnosis of XP in
patients from Maghrebi descent. We therefore suggest that
the XP patients from Maghreb, initially specifically test for the
XPA-R228X and XPC-p.Val548AlafsX25 mutations. In the
absence of these mutations, unscheduled DNA synthesis on
cultured fibroblasts should be performed to confirm the DNA
repair defect, complementation analysis using recombinant
retroviruses should determine the involved gene followed by
sequencing analysis of the corresponding XP gene.
MATERIALS AND METHODS
We obtained an institutional approval of experiments and written
informed consent for each patient included in the study. This study
was in conformity to the Helsinki Guidelines.
Families with xeroderma pigmentosum features
We studied 86 XP patients belonging to 66 different unrelated XP
families clinically diagnosed as possible XP patients. Two types of
analysis were performed. A direct sequencing of the XP genes (XPC,
XPA, XPD/ERCC2, XPV/POLH and then XPB, XPE, XPF, and XPG)
was realized in a group of 57 patients belonging to 44 families
(called thereafter ‘‘Direct sequencing analysis’’). A more biological
approach, in which the DNA repair level was first quantified by
unscheduled DNA synthesis on cultured skin fibroblasts followed by
complementation with wild-type DNA repair genes to determine the
right gene for sequencing (called thereafter ‘‘DNA repair analysis’’)
was performed on 22 distinct families (29 patients in total, 22
probands and seven affected relatives).
Informed consent was obtained from all the patients or the
parents of minor children.
In the direct sequencing analysis, 42 probands originated from
the Maghreb region of North Africa, including Morocco (24), Algeria
(14) and Tunisia (4); one patient was European (Spain), and one
French patient had French West Indies and Chile ancestries. In the
DNA repair analysis, 17 families originated from North Africa, three
patients from France, one from Spain, and one from Greece.
Clinical data were available in 60 of the 66 families and in 73 of
the 86 patients. Mean age of XP patients was 16 years (range, 2–45
years). Sex ratio M/F was 0.8. Fourteen patients had no familial
history of XP, 31 patients had at least one related affected by XP, and
in the 21 remaining families, this information was unknown.
Consanguinity was confirmed in 25 of 45 families, but could not
be documented in 21 families.
XP symptoms began at a mean age of 42 months. Skin
photosensitivity was present in most patients, with poikilodermia
in 92%, xeroderma in 94%, skin atrophy in 77%, and telangiectasia
in 74% of XP patients. Skin tumors occurred in 71% of XP patients,
1540 Journal of Investigative Dermatology (2010), Volume 130
N Soufir et al.
Prevalent Mutations in Xeroderma Pigmentosum C
with BCC in 65%, SCC in 49%, and melanoma in 18% of patients.
Atypical fibroxanthomas were observed in three patients, and
malignant histiocytofibroma in one patient. Ophthalmological
symptoms were present in most patients: photophobia in 81%,
conjunctivitis in 79%, and keratitis and ectropion in 29% of XP
patients. Ocular tumors occurred in 10% of patients. Neurological
symptoms, mainly represented by mental retardation and pyramidal
ataxia, were noted in nine patients.
In addition, two patients had a cerebral glioma, one patient had
a lymphoma and another patient an acute lymphocytic leukemia
(ALL).
DNA repair investigation
The response to UV irradiation was analyzed by measuring
unscheduled DNA synthesis in primary fibroblast cultures estab-
lished from biopsies of unaffected skin, as previously described
(Sarasin et al., 1992). The characterization of XP genetic defect
was carried out by classical complementation assays using
recombinant retroviruses as already published (Arnaudeau-Begard
et al., 2003).
Sequence analyses of XP genes
Genomic DNA was extracted from peripheral blood samples or
cultured cells (fibroblasts and lymphoblasts) using standard proce-
dures in the different laboratories involved in the study. Complete
coding sequences were carried out and repeated at least twice. The
XPC gene was amplified by PCR in 15 exonic fragments,
encompassing the 16 exons of the gene and the corresponding
intron–exon junctions, as described (Khan et al., 2002; Jacobelli
et al., 2008) by using Taq Gold DNA polymerase (Perkin Elmer,
Courtaboeuf, France). The XPA gene was amplified in six exonic
fragments. The 23 exons of the XPD/ERCC2 gene and the 10 coding
exons of XPV/POLH were analyzed in patients who carried no
mutation of either XPC or XPA gene.
Automatic sequencing was performed on both strands using
BigDye Terminator Cycle Sequencing Ready Reaction Kit on the ABI
PRISM 7700 automated sequencer (Perkin Elmer). Mutations and
polymorphisms were identified using SeqScape software (Perkin
Elmer). Mutation numbering is based on Genbank cDNA sequences
(NM_004628 and NM_000380, for XPC, and XPA, respectively) with
a ‘‘c’’ symbol before the number and uses the A of the ATG
translation initiation start as nucleotide 1. Protein numbering (‘‘p’’
symbol) starts from the initiating methionine (codon 1). Common
polymorphisms of the XPC gene have been previously described
(Chavanne et al., 2000; Rivera-Begeman et al., 2007).
XPC haplotype analysis
Two intragenic XPC polymorphic microsatellites were analyzed with
the following primers: sat1U-50F-GCCTAAGATACCTGAGGTACA
CTTTCA-30, sat1L 50-GAATATACACATCCAAGGACCTCAAGT-30,
sat2U50-F-GGGTTTGAGACCAGCTTGGGC-30, and sat2L 50-CGC
CATCATTATGTTGTTGCATTC-30. Fluorescent PCR products were
run on the automatic sequencer and analyzed using the GeneMap-
per software (Perkin Elmer). In addition, the analysis of 11 bi-allelic
polymorphisms, localized both in the coding sequence and the
flanking intronic sequences of XPC, was performed in XP-C patients
carrying the common mutation and in 49 unrelated healthy controls
from North Africa (Algeria and Morocco). The SNPs are localized as
follows: c.1-27 G4C, c.621þ 44 C4G, c.891-22 A4G, c.1475
G4A (p.R492H), c.1496 C4T (p.A499V), c.2061 G4A (p.R687R),
c.2251-37 C4G, c.2251-6 A4C, c.2604þ 28 C4G, c.2515-40
A4G, c.2815 C4A (p.Q939K).
Estimate of the age and growth rate of the XPC
c.1643_1644delTG (p.Val548AlafsX25) mutation
We used the method developed by Austerlitz et al. (2003) that
provides a joint estimate of the age of the mutation—that is, the time
elapsed since the appearance of the common ancestor of the
mutation carriers in the population and the growth rate of the
number of copies since this appearance. For this purpose, 11
microsatellites surrounding the XP locus were identified by using the
Human Genome Browser gateway (http://genome.ucsc.edu/cgi-bin/
hgGateway) (Supplementary Table S1). These microsatellites were
genotyped in 30 unrelated patients (probands) carrying the XPC
c.1643_1644delTG (p.Val548AlafsX25) mutation and in 25 of their
relatives. As for XPC intragenic microsatellites, fluorescent PCR
products were run on the automatic sequencer and analyzed using
the GeneMapper software (Perkin Elmer).
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